|
|
By George Vratsanos, MD, and Dawn Waterworth, Ph.D., Janssen Immunology
In large pharma, R&D investment is increasingly expensive. In academia, there is pressure to produce high-profile science for the improvement of public health. Collaboration between industry and academia is key to innovation and addressing the unmet needs of patients.
|